A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer

Trial Profile

A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 May 2017

At a glance

  • Drugs NTX 010 (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Mar 2017 Status changed from active, no longer recruiting to discontinued, as interim analysis declared futility.
    • 31 May 2013 Results of the pre-planned interim futility analysis presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 31 May 2013 Status changed from recruiting to active no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top